Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

How to: Unusual Volume

Bell Direct
September 2, 2020

Morning Bell 2 September

Jessica Amir
September 2, 2020

How to: Directors’ Interest tool

Bell Direct
September 1, 2020

Morning Bell 1 September

Jessica Amir
September 1, 2020

How to: Changes in Substantial Holdings

Jessica Amir
August 31, 2020

Morning Bell 31 August

Jessica Amir
August 31, 2020

How to: Upcoming Dividends tool

Jessica Amir
August 30, 2020

How to: Visual Depth Chart

Jessica Amir
August 29, 2020

How to: Market to Limit vs. Limit

Jessica Amir
August 28, 2020

Weekly Wrap 28 August

Bell Direct
August 28, 2020

Morning Bell 28 August

Jessica Amir
August 28, 2020